Eloxx Pharmaceuticals Inc
2939900.0 %
234.09 %
Yet to be announced
Company Overview
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel ribonucleic acid (RNA)-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. The company's lead drug candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins.
The company is primarily engaged in research and development activities and has not yet generated any revenue from product sales. Their focus is on developing treatments for genetic diseases including cystic fibrosis and other diseases caused by nonsense mutations.
Revenue Sources
PassThe company is currently in the research and development phase and has not generated any revenue in the past four quarters. As a pre-revenue biotech company developing treatments for genetic diseases, their business model and intended products are halal-compliant.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|
The company is pre-revenue and still in R&D phase. During the last four quarters, the company reported zero interest income and zero interest expense. Given the company's pre-revenue status, we skip the interest ratio calculations as per the methodology for pre-revenue companies.
Operational Ethics
PassBased on review of company filings, public records, and available information, there is no evidence of significant ongoing associations with entities involved in human rights violations such as the state of Israel or the Chinese Communist Party.
Comments